Kazia Therapeutics Limited (KZIA) News
Track canonical SquawkNews coverage tagged to KZIA, Kazia Therapeutics Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Analysts initiate coverage on ACHV, ALGM, KZIA, MTSI, PLYX, SBSW
Several brokers initiate or reiterate bullish coverage on ACHV, ALGM, KZIA, MTSI, PLYX and SBSW, including overweight, buy and strong buy ratings.
EQUITY | Aug 13, 2026, 10:50 AM UTC
L
KZIA Kazia Therapeutics announces the filing of provisional patent for novel strategy, supported by preclinical data, to prevent metastatic
KZIA Kazia Therapeutics announces the filing of provisional patent for novel strategy, supported by preclinical data, to prevent metastatic recurrence in triple-negative breast cancer
EQUITY | Jul 28, 2026, 11:31 AM UTC
L
BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34
BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ: KZIA ) with a Buy rating and announces Price Target of $34.
EQUITY | Jul 01, 2026, 11:36 AM UTC